Chief Medical Officer

Introduction Hlx is partnering with a clinical-stage biotechnology company developing innovative therapies for rare renal diseases. With a lead programme in Phase II, the company is entering a critical stage of development and value creation. We are seeking a hands-on Chief Medical Officer to work closely with the CEO as a true strategic partner. This role combines leadership and execution, with a strong emphasis on external engagement across investors, Key Opinion Leaders, and partners. The successful candidate will play a central role in shaping both the clinical strategy and the broader company narrative. Responsibilities Lead the clinical development strategy and execution for the companys Phase II programme and pipeline Provide hands-on oversight of trial design, execution, and data interpretation in a lean operating model Act as a key partner to the CEO on company strategy, prioritisation, and growth initiatives Play a central role in investor engagement, including fundraising, diligence, and presenting to investors and the Board Build and maintain strong relationships with global KOLs, investigators, and patient advocacy groups Represent the company at scientific congresses and industry events Lead regulatory interactions (FDA, EMA) and overall development pathway Integrate translational insights, including biomarkers and patient stratification strategies Support the build-out of the clinical and medical function as the company scales Qualifications MD or MD/PhD; nephrology expertise strongly preferred - Ideally nephrologist or, cardio/metabolic focused Proven track record leading clinical development programmes through Phase II Demonstrated experience working closely with investors and KOLs in an externally facing capacity Prior experience in a small or mid-sized biotech environment preferred Strong strategic and operational capabilities; able to operate in a hands-on, resource-conscious setting Excellent communication skills with the ability to translate complex science for diverse audiences Credible external presence with regulators, investigators, and the investment community Next Steps For a confidential discussion or to express interest, please get in touch directly. We are actively engaging with a select group of candidates and welcome early conversations.

Created: 2026-04-06